{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"14.7","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with neuroblastoma","id":"OG000","title":"Cohort 3"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"PFS as Determined by the Investigator Using irRC for Participants With Neuroblastoma","type":"SECONDARY","unitOfMeasure":"Months"}